Partnership14 Feb 2026, 04:00 pm
Shilpa Medicare Enters Strategic Partnership with NXI Therapeutics for Autoimmune Therapy Development
AI Summary
Shilpa Medicare Limited has entered into a strategic partnership with NXI Therapeutics AG, Switzerland, for the long-term development and commercial manufacturing of a novel therapy to treat autoimmune or alloimmune disorders. This partnership is expected to strengthen Shilpa Medicare's capability and know-how in innovative therapies, with the potential for multi-year commercial supply. The agreement includes milestone-linked expansion potential and remains confidential.
Key Highlights
- Shilpa Medicare to provide comprehensive CMC development, process scale-up, GMP clinical supply, and commercial manufacturing support for NXI Therapeutics' immunomodulatory program.
- The partnership spans early development through commercialization, positioning Shilpa as a lifecycle partner for the program.
- The autoimmune and immune-modulation segment represents one of the fastest-growing therapeutic categories globally.
- This partnership marks the third significant international development and manufacturing contract secured by Shilpa group.
- Shilpa Medicare continues to strengthen its position as a trusted development and commercial manufacturing partner in high-growth therapeutic segments.